Alembic Pharmaceuticals rises on getting USFDA`s final approval for Tretinoin Cream
Alembic Pharmaceuticals is currently trading at Rs. 966.50, up by 8.25 points or 0.86% from its previous closing of Rs. 958.25 on the BSE.
The scrip opened at Rs. 965.00 and has touched a high and low of Rs. 980.05 and Rs. 965.00 respectively. So far 430 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1296.15 on 09-Oct-2024 and a 52 week low of Rs. 725.60 on 03-Mar-2025.
Last one week high and low of the scrip stood at Rs. 980.05 and Rs. 923.30 respectively. The current market cap of the company is Rs. 18835.66 crore.
The promoters holding in the company stood at 69.67%, while Institutions and Non-Institutions held 20.42% and 9.90% respectively.
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Tretinoin Cream USP, 0.025%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Retin-A Cream, 0.025%, of Bausch Health US, LLC. Tretinoin cream is indicated for topical application in the treatment of acne vulgaris. Refer label for a detailed indication.
Tretinoin cream USP, 0.025%, has an estimated market size of $94 million for twelve months ending June 2025 according to IQVIA. The company has a cumulative total of 224 ANDA approvals (202 final approvals and 22 tentative approvals).
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
